Clonazepam and milnacipran in the treatment of patients with panic disorder and comorbid major depression

Primary Care and Community Psychiatry

Volumn 11, Issue 2, 2006, Pages 51-56

  Cía, Alfredo H ^a,b   Brizuela, Julio A ^a   Cascardo, Enzo ^a   Varela, Maria F ^a  

^a Clínica Moravia   (Argentina)

^b NONE   (Argentina)

Author keywords

Clonazepan; Comorbidity; Major depression; Milnacipran; Panic disorder

Indexed keywords

CLONAZEPAM; MILNACIPRAN;

ADULT; AGORAPHOBIA; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FEMALE; HUMAN; INSOMNIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; OUTPATIENT; PANIC; PRIORITY JOURNAL;

EID: 33751320957     PISSN: 17468841     EISSN: 14734885     Source Type: Journal    
DOI: 10.1185/135525706X105037     Document Type: Article

References (20)

1. Roy-Byrne PP, Wagner AW, Schraufnagel TJ. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry 2005;66 (Suppl 4):16-22
2. Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry 2004;65 (Suppl 17):19-28
3. Lader M. Management of panic disorder. Expert Rev Neurother 2005;5:259-66
4. Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry 2005;66 (Suppl 4):23-7
5. Susman J, Klee B. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry 2005;7:5-11
6. Rickels K, Schweizer E. The clinical course and longterm management of generalized anxiety disorder. J Clin Psychopharmacol 1990;10(Suppl 3):101S-110S
7. Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 1999;60 (Suppl 22):18-22
8. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002;63 (Suppl 14):9-16
9. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002;63 (Suppl 8):17-23
10. Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, Otto MW. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003;17:276-82
11. Bakker A, van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 2005;8:473-8
12. Pollack MH, Worthington JJ 3rd, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996;32:667-70
13. Katzman M. Venlafaxine in the treatment of anxiety disorders. Expert Rev Neurother 2004;4:371-81
14. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10: 732-47
15. Ansseau M, von Frenckell R, Serre C. Pilot study of milnacipran in panic disorder. Eur Psychiatry 1991;6:103-5
16. Kaufman J, Charney D. Comorbidity of mood and anxiety disorders. Depress Anxiety 2000;12 (Suppl 1):69-76
17. Dindo L, Coryell W. Comorbid major depression and panic disorder: significance of temporal sequencing to familial transmission. J Affect Disord 2004;82:119-23
18. Nutt DJ. Care of depressed patients with anxiety symptoms. J Clin Psychiatry 1999;60 (Suppl 17):23-7; discussion 46-8
19. Kjernisted KD, Bleau P. Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry 2004;49(Suppl 1):51S-63S
20. Tsukamoto T, Kondoh R, Ichikawa K. Efficacy and safety of milnacipran in the treatment of generalized anxiety disorder: an open study Int J Psychiatry Clin Pract 2004;8: 255-8